why choose us

First received: August 24, 2023

Clinical Trial: Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Borderline Resectable Carcinoma

Study Type: INTERVENTIONAL


Official Title: Phase II Study of Neoadjuvant Durvalumab (MEDI4736) and Tremelimumab in Combination With Gemcitabine and Cisplatin in Patients With Intrahepatic Cholangiocarcinoma That is Borderline Resectable/R

Brief Summary: The goal of this clinical trial is to test feasibility and safety of the combination of tremelimumab and durvalumab plus gemcitabine and cisplatin as a neoadjuvant treatment bridge patients to a curative resection in treatment naïve borderline resectable, or resectable with high risk for recurrence intrahepatic cholangiocarcinoma patients.The main question[s] it aims to answer are:What is the rate of conversion of unresectable tumor to resectable cancer?What are the side effects of this treatment…

Read more